Bayer's Nexavar gets Chinese nod; Cephalon sues Barr over Fentora patent;

> Bayer and Onyx Pharmaceuticals got approval from Chinese drug regulators to market their Nexavar drug for liver cancer. Report

> Cephalon sued Barr Pharmaceuticals for patent infringement over its Fentora cancer pain drug, after Barr asked the FDA to approve its generic version. Report

> India's Glenmark Pharmaceuticals posted a 101.9 percent increase in fiscal first-quarter profits on strong growth in its generics business. Report

> Watson Pharmaceuticals named Clare Carmichael as senior vice president for human resources, replacing Susan Skara, who retired. Release

> SiCap, an Albany-area company known for its "Sinus Buster" nasal sprays, has been acquired by Dynova Laboratories, a private-equity-funded venture. Report

> In another instance of the industry teaming up with academia, GlaxoSmithKline and Harvard Stem Cell Institute (HSCI) announced that they have signed a five-year, $25 million pact to research and possibly develop stem cell drugs. Report

> New Jersey-based nutraceutical company Integrated Biopharma is spinning off its interest in iBioPharma to form a stand-alone biotech company. Report

> CHMP announced today the recommendation of Bayer's Xarelto, known generically as rivaroxaban. Report

And Finally... Anxiety and depression double the risk of type 2 diabetes in men, a study shows. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.